Personalis
Jenevieve Fisher, R.T.(R)(T), has a diverse work experience spanning various roles and industries. Jenevieve currently serves as the Regional Director of Sales and Director of Pediatric Initiatives at Personalis, Inc. In 2015, they founded Sower Media Group, a company focused on children's health education media. Prior to that, they founded Educate A Cure, a non-profit organization dedicated to children and family education about diseases and disabilities. Jenevieve also held the position of Regional Director of Sales at Sema4 from 2020 to 2022. Jenevieve worked as a Medical Writer and Professional Editor from 2009 to 2016 and was a Consultant for Naturopathic and Functional Medicine Physicians and clinics from 2002 to 2016. In addition, they were the Director of Marketing and Development at the American Anti-Cancer Institute from 2011 to 2014. Jenevieve's early career included roles as a Radiation Oncology Therapist specializing in pediatrics at the Fred Hutchinson Cancer Research Center from 1999 to 2011 and Swedish Hospital's Tumor Institute from 1996 to 1998. Jenevieve'sexpertise includes various radiation oncology treatments and techniques as well as an interest in dosimetry, CT, MRI, Gamma Knife Radiosurgery, and interstitial brachytherapy.
Jenevieve Fisher, R.T.(R)(T), received their education in Radiation and Imaging Sciences from Bellevue College from 1993 to 1996. Jenevieve is also certified as an R.T.(R)(T) by the American Society of Radiologic Technologists.
This person is not in the org chart
This person is not in any offices
Personalis
4 followers
Personalis is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA Million Veteran Program (MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited.